HOUSTON--(BUSINESS WIRE)--PLx Pharma, a pharmaceutical company developing gastrointestinal (GI) safer formulations of proven non-steroidal anti-inflammatory drugs (NSAIDs), announced today the expansion of its Board of Directors with the appointment of a distinguished industry leader, Michael J. Valentino, as Chairman of the Board. “We are very pleased to have Mike Valentino join PLx’s team of world-class advisors,” stated Ron Zimmerman, president and chief executive officer of PLx Pharma. “Mike’s exceptional industry and commercialization experience with a range of OTC and Rx drug products will be extremely valuable as we advance our lead product, a GI safer aspirin, PL2200 Aspirin 325 mg and other products toward the consumer health and prescription markets. We are grateful to have access to Mike’s proven leadership and experience.”
